Replacing plasmid DNA with enzymatically produced DNA in your AAV production eliminates many issues around complex or unstable sequences, purity, speed to manufacture, safety and scalability. Many biotech and pharma…
Read More
Transient transfection remains the most widely used method for AAV manufacturing, but it can be difficult to optimize due to competing process requirements. Factors such as cell density, DNA concentration,…
Read More
As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) remains a limiting factor, slowed by scalability challenges, bacterial contamination…
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
TOM MERRITT, PH.D. Traditional methods for the production of adeno-associated viral (AAV) vectors — crucial components in gene therapies — rely on plasmid DNA (pDNA), which can pose safety concerns…
Read More
